Natera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) P/S ratio
As of 5 November 2026, Natera, Inc. (NTRA) trades at a P/S ratio of 18.1×. Over the past ten years it has ranged from 0.3× (September 2015) to 25.8× (February 2021); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of 4.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 13.6× | 16.74% |
| FY2024 | 11.6× | 76.88% |
| FY2023 | 6.6× | 42.43% |
| FY2022 | 4.6× | (65.85%) |
| FY2021 | 13.5× | (34.43%) |
| FY2020 | 20.6× | 166.02% |
| FY2019 | 7.8× | 147.29% |
| FY2018 | 3.1× | 30.14% |
| FY2017 | 2.4× | (16.54%) |
| FY2016 | 2.9× | 94.10% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 20.5× | 42.48% |
| Jun 2026 | 14.4× | 26.97% |
| Mar 2026 | 11.3× | (16.69%) |
| Dec 2025 | 13.6× | 30.18% |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| LH Labcorp Holdings Inc. compare | 2.0× |
| DGX Quest Diagnostics Incorporated compare | 2.4× |
| IQV IQVIA Holdings Inc. compare | 2.5× |
| A Agilent Technologies, Inc. compare | 6.6× |
| ILMN Illumina, Inc. compare | 7.0× |
| WAT Waters Corporation compare | 8.0× |
| MTD Mettler-Toledo International, Inc. compare | 8.2× |
| IDXX IDEXX Laboratories, Inc. compare | 11.3× |
| NTRA Natera, Inc. | 18.1× |
| Diagnostics & Research industry median | 4.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on NTRA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement